This is a demo store. No orders will be fulfilled.

 
Call +1 (833) 552-7181 or Contact us
Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings
྾
main product photo

Rifalazil - 99%, high purity , DNA-directed RNA polymerase inhibitor, CAS No.129791-92-0, DNA-directed RNA polymerase inhibitor

COA COA
    Grade & Purity:
  • ≥99%
In stock
Item Number
R651163
Grouped product items
SKU Size
Availability
 Price Qty
R651163-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$680.90
R651163-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,320.90
R651163-250mg
250mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,550.90
Wish List
Bulk Order  SDS  DATASHEET  Specification Sheet
View related series
Bacterial (3013) Cell Cycle (2830) Cell Cycle/DNA Damage (2602) DNA/RNA Synthesis (362)

Basic Description

Synonyms Q-103229 | 2,7-(Epoxy[1,11,13]pentadecatrienoimino)-6H-benzofuro[4,5-a]phenoxazine-1,6,15(2H)-trione, 25-(acetyloxy)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-[4-(2-methylpropyl)-1-piperazinyl]-, (2S,16Z,18E,20S,21S,22R,23R,24R,
Specifications & Purity ≥99%
Biochemical and Physiological Mechanisms Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit inxa0RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic , exhibits high p
Storage Temp Store at 2-8°C,Desiccated
Shipped In
Wet ice
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type INHIBITOR
Mechanism of action DNA-directed RNA polymerase inhibitor
Product Description

Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase Rifalazil (KRM-1648; ABI-1648) is an antibiotic , exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori , C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)

In Vitro

Rifalazil exhibits antimicrobal activity against Gram-positive enteric bacteria, inhibits Clostridium difficile , Clostridium perfringens , Bacteroides fragilis with MIC 50 value of 0.0015, 0.0039, 0.0313 µg/ml, respectively. Rifalazil exhibits antimicrobal activity against Gram-negative enteric bacteria, inhibits Escherichia coli and Klebsiella pneumoniae with MIC 50 value of 16 and 16 µg/ml, respectively. Rifalazil exhibits antimicrobal activity against non-enteric Gram-positive bacteria, inhibits Methicillin-susceptible Staphylococcus aureus , Methicillin-resistant S. aureus , Methicillin- and quinolone-resistant S. aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Streptococcus pneumoniae with MIC 50 value of 0.0078, 0.0078, 0.0078, 0.0078, 0.0002, 0.0001 µg/ml, respectively. Rifalazil exhibits antimicrobal activity against Helicobacter pylori , Chlamydia pneumoniae and Chlamydia trachomatis with MIC 50 value of 0.004, 0.000125 and 0.00025 µg/ml, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rifalazil (oral gavage; 20, 25, and 150 mg/kg; 6-8 weeks) combines with isoniazid (INH) for 6 weeks or greater significantly reduced the number of mice per group in which M. tuberculosis is detected in both spleens and lungs compared to the reductions for the early and late controls. And the addition of Pyrazinamide (PZA) does not significantly improve RLZ-INH therapy at any time point. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female CD-1 mice infected with 5.2 × 10 7 viable mycobacteriaDosage: 20, 25, and 150 mg/kg; 6-8 weeks Administration: Oral gavage Result: Combined with isoniazid (INH) showed its potential for short-course treatment of Mycobacterium tuberculosis infection.

Form:Solid

IC50& Target:IC50: RNA polymerase

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Organoheterocyclic compounds
Class Benzoxazines
Subclass Phenoxazines
Intermediate Tree Nodes Not available
Direct Parent Phenoxazines
Alternative Parents N-arylpiperazines  Naphthols and derivatives  Dialkylarylamines  N-alkylpiperazines  Ketals  Vinylogous amides  Vinylogous acids  Heteroaromatic compounds  Cyclic carboximidic acids  Trialkylamines  Secondary alcohols  Carboxylic acid esters  Amino acids and derivatives  Propargyl-type 1,3-dipolar organic compounds  Polyols  Oxacyclic compounds  Monocarboxylic acids and derivatives  Dialkyl ethers  Azacyclic compounds  Organopnictogen compounds  Organic oxides  Hydrocarbon derivatives  Carbonyl compounds  
Molecular Framework Aromatic heteropolycyclic compounds
Substituents Phenoxazine - N-arylpiperazine - 1-naphthol - Naphthalene - Dialkylarylamine - Tertiary aliphatic/aromatic amine - Ketal - N-alkylpiperazine - Benzenoid - Piperazine - 1,4-diazinane - Heteroaromatic compound - Vinylogous amide - Vinylogous acid - Cyclic carboximidic acid - Tertiary aliphatic amine - Tertiary amine - Secondary alcohol - Carboxylic acid ester - Amino acid or derivatives - Oxacycle - Azacycle - Organic 1,3-dipolar compound - Propargyl-type 1,3-dipolar organic compound - Polyol - Monocarboxylic acid or derivatives - Ether - Dialkyl ether - Carboxylic acid derivative - Acetal - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Carbonyl group - Amine - Alcohol - Aromatic heteropolycyclic compound
Description This compound belongs to the class of organic compounds known as phenoxazines. These are polycyclic aromatic compounds containing a phenoxazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a 1,4-oxazine ring.
External Descriptors Not available

Product Properties

ALogP 3.3

Associated Targets(Human)

NR1I2 Tchem Pregnane X receptor (6667 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Homo sapiens (32628 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Associated Targets(non-human)

Chlamydia pneumoniae (241 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Helicobacter pylori (3113 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Staphylococcus aureus (210822 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Clostridioides difficile (2968 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mycobacterium tuberculosis (203094 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mycobacterium leprae (477 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Names and Identifiers

IUPAC Name [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-[4-(2-methylpropyl)piperazin-1-yl]-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate
INCHI InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,58-60,62H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29+,34-,42-,43+,46+,51-/m0/s1
InChIKey IXSVOCGZBUJEPI-HTQYORAHSA-N
Smiles CC1C=CC=C(C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C(C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)C
Isomeric SMILES C[C@H]1/C=C/C=C(\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)/C
Alternate CAS 129791-92-0
PubChem CID 135431094
MeSH Entry Terms 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin;ABI 1648;ABI-1648;ABI1648;benzoxazinorifamycin;KRM 1648;KRM-1648;rifalazil
Molecular Weight 941.07

Certificates（CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Chemical and Physical Properties

Solubility DMSO : 8.33 mg/mL (8.85 mM; Need ultrasonic)
Molecular Weight 941.100 g/mol
XLogP3 3.300
Hydrogen Bond Donor Count 5
Hydrogen Bond Acceptor Count 16
Rotatable Bond Count 6
Exact Mass 940.447 Da
Monoisotopic Mass 940.447 Da
Topological Polar Surface Area 226.000 Ų
Heavy Atom Count 68
Formal Charge 0
Complexity 2510.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 9
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 3
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 3
Covalently-Bonded Unit Count 1

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.